Naraya (Drospirenone, Ethinylestradiol)

Naraya, a combined estrogen‑progestogen oral contraceptive, is indicated for hormonal contraception.

• Prevention of pregnancy: provides reliable contraceptive protection when taken as prescribed.
• Management of menstrual disorders: helps regulate menstrual cycles and may reduce heavy bleeding.
• Treatment of moderate acne: can improve acne associated with hormonal fluctuations.

• Drospirenone acts as a progestogenic agent that suppresses the luteinizing hormone surge, thereby inhibiting ovulation. Ethinylestradiol provides estrogenic activity that stabilises the endometrium and enhances the contraceptive effect. Together they thicken cervical mucus, making sperm penetration difficult, and induce endometrial changes that prevent implantation.

Common Side Effects

• Nausea: mild to moderate stomach upset.
• Breast tenderness: temporary discomfort in the breast tissue.
• Headache: occasional mild to moderate headache.
• Weight gain: slight increase in body weight.
• Mood changes: fluctuations in mood or emotional state.
• Spotting: irregular vaginal bleeding between periods.

Serious or Rare Side Effects

• Venous thromboembolism: blood clots in deep veins or lungs.
• Arterial thrombosis: clot formation in arteries leading to stroke or heart attack.
• Hypertension: significant increase in blood pressure.
• Liver disorders: jaundice or abnormal liver function tests.
• Gallbladder disease: inflammation or stones.
• Severe allergic reactions: rash, swelling, or anaphylaxis.

Before initiating Naraya, consider the following precautions.

• Thrombotic risk assessment: evaluate personal or family history of clotting disorders.
• Smoking status: avoid use in women over 35 who smoke.
• Hypertension monitoring: check blood pressure regularly.
• Liver disease evaluation: contraindicated in active liver disease.
• Migraine with aura: use with caution due to increased stroke risk.
• Store at ambient temperature: keep below 25 °C, in the original packaging, protected from moisture and light.

Naraya may interact with other medicines; review patient medication lists.

Major Interactions (Avoid)

• Strong CYP3A4 inducers (e.g., rifampin, phenytoin, carbamazepine): may reduce contraceptive efficacy.
• St. John’s wort: can decrease hormone levels, leading to breakthrough bleeding.
• Certain antibiotics (e.g., griseofulvin): may lower plasma concentrations.

Moderate Interactions (Monitor Closely)

• Antifungal agents (e.g., ketoconazole, itraconazole): may increase hormone levels and side‑effect risk.
• Antidepressants (SSRIs, SNRIs): may heighten risk of mood changes.
• Antihypertensives: monitor blood pressure as estrogen can affect vascular tone.